Buy Fluticasone + Salmeterol

Fluticasone + Salmeterol

Fluticasone + Salmeterol: Inhaler Overview

Fluticasone + Salmeterol is a fixed-dose combination inhaler that contains the corticosteroid fluticasone propionate and the long-acting β2-agonist salmeterol xinafoate. It belongs to the therapeutic class - asthma and breathing disorders - and is marketed in inhaler formats delivering two strengths: 250 µg / 50 µg and 500 µg / 50 µg per actuation. In Hong Kong the product is prescription-only and is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance.

How Fluticasone + Salmeterol Works in the Body

• Fluticasone propionate is an inhaled corticosteroid (ICS). It binds to glucocorticoid receptors in airway cells, reducing the production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This anti-inflammatory action lessens airway swelling, mucus production, and hyper-responsiveness.
• Salmeterol xinafoate is a long-acting β2-adrenergic agonist (LABA). By stimulating β2 receptors on airway smooth muscle, it triggers relaxation of the bronchi, leading to bronchodilation that begins within 15 minutes, peaks at about 2 hours, and can last up to 12 hours.
• The combination provides maintenance control: the steroid controls underlying inflammation while the LABA maintains airway openness, improving overall asthma or COPD control when taken regularly.

Conditions Treated with Fluticasone + Salmeterol

• Persistent asthma (moderate to severe) that requires daily maintenance therapy in addition to short-acting reliever inhalers.
• Chronic obstructive pulmonary disease (COPD) with a history of exacerbations, when a long-acting bronchodilator plus anti-inflammatory therapy is indicated.

These indications follow the approvals granted by the U.S. FDA and the European Medicines Agency and are recognized by the Hong Kong Department of Health for clinical use.

Patient Suitability and Contraindications

Who May Benefit

• Adults and adolescents (≥12 years) with persistent asthma who need both anti-inflammatory and bronchodilator effects.
• Adults with COPD who have experienced frequent exacerbations despite using a single long-acting bronchodilator.

Absolute Contraindications

• Known hypersensitivity to fluticasone, salmeterol, or any excipient in the inhaler.
• Past severe hypersensitivity reaction to any inhaled corticosteroid or LABA.

Relative Contraindications / Cautions

• Pregnancy and lactation - fluticasone is classified as Category C (risk cannot be ruled out). Salmeterol may affect fetal growth; use only if the potential benefit justifies the risk.
• Severe hepatic impairment - systemic exposure to fluticasone may increase; dose adjustment or alternative therapy should be considered.
• Cardiovascular disease - LABA can cause tachycardia or palpitations; monitor patients with arrhythmias or uncontrolled hypertension.

Special Populations

• Elderly patients may be more susceptible to systemic corticosteroid effects (e.g., bone loss).
• Patients with active or untreated infections (including fungal, bacterial, or viral) should receive appropriate antimicrobial therapy before initiating treatment.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Oral thrush (candidiasis) - frequently reported; rinse mouth after each inhalation.
• Hoarseness or dysphonia - typically mild and improves with proper inhaler technique.
• Headache - occasional, transient.

Serious Adverse Events

• Paradoxical bronchospasm - sudden worsening of breathing after inhalation; seek immediate medical attention.
• Severe hypersensitivity reactions - angioedema, urticaria, or anaphylaxis require emergency care.
• Systemic corticosteroid effects (rare at inhaled doses) - adrenal suppression, osteoporosis, cataracts.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can raise systemic fluticasone levels, increasing the risk of steroid-related side effects.
• Beta-blockers (non-selective) may blunt the bronchodilator effect of salmeterol, potentially worsening asthma control.
• Diuretics, digoxin, or anti-arrhythmic drugs - monitor for additive cardiac effects when using salmeterol.

Food and Lifestyle Interactions

• No specific food restrictions; the inhaler can be used with or without meals.
• Alcohol does not interfere with the inhaler’s action, but excessive consumption may exacerbate asthma symptoms.
• Caution when operating heavy machinery or driving until the individual knows how the medication affects them, as transient tachycardia or tremor can occur.

How to Take Fluticasone + Salmeterol

• Standard dosing (based on the two available strengths):

• 250 µg / 50 µg: 1 inhalation twice daily (morning and evening).

• 500 µg / 50 µg: 1 inhalation twice daily.

• Administration tips:

• Prime the inhaler according to the manufacturer’s instructions before first use.

• Exhale fully, place the mouthpiece between the lips, and inhale steady and deep while activating the device.

• Hold breath for about 10 seconds after inhalation, then exhale slowly.

• Rinse mouth with water (do not swallow) after each dose to reduce the risk of oral thrush.

• Missed dose - Take the missed inhalation as soon as you remember if it is at least 2 hours before the next scheduled dose; otherwise, skip the missed dose and resume the regular schedule. Do not double the dose.

• Overdose - May present with severe systemic corticosteroid effects (e.g., adrenal suppression) and exaggerated β2-agonist activity (tachycardia, tremor, hypokalemia). Seek emergency medical care; treatment is supportive, and glucocorticoid antagonists are not indicated.

• Discontinuation - Do not stop abruptly if the inhaler has been used regularly for more than a few weeks. Reduce the dose gradually under medical supervision to avoid loss of asthma control.

Monitoring and Follow-Up

• Asthma control - Review symptom scores, rescue inhaler use, and peak expiratory flow (PEF) every 1-3 months.
• Lung function - Spirometry at baseline and periodically (typically every 6-12 months) to assess FEV₁ changes.
• Safety labs - Consider serum cortisol testing in patients on high-dose inhaled steroids for more than 3 months; check potassium levels if high doses of salmeterol are used with diuretics.
• Bone health - In long-term high-dose steroid users, assess bone mineral density according to local osteoporosis guidelines.

Storage and Handling

• Keep the inhaler at room temperature (below 30 °C) and protect it from moisture and direct sunlight.
• Store out of reach of children; many inhalers include a child-proof cap.
• Do not expose the device to freezing temperatures.
• Replace the inhaler after the indicated number of actuations (usually 120 doses) or when the dose counter reaches zero, even if some medication appears to remain.

Medication-Specific Glossary

Inhaled Corticosteroid (ICS)

A steroid medication formulated for inhalation that reduces airway inflammation with minimal systemic absorption compared with oral steroids.

Long-Acting β2-Agonist (LABA)

A bronchodilator that selectively stimulates β2-adrenergic receptors, providing prolonged airway smooth-muscle relaxation for up to 12 hours.

Paradoxical Bronchospasm

An unexpected tightening of the airways that occurs immediately after inhalation of a medication intended to open them.

Adrenal Suppression

Reduced endogenous cortisol production caused by prolonged exposure to corticosteroids; may become clinically relevant with high systemic steroid levels.

Medical Disclaimer

This article provides educational information about Fluticasone + Salmeterol and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.